Document ID: chunk:federal_register_of_legislation:F2022C00585:reg:9:p1
Version: federal_register_of_legislation:F2022C00585
Segment Type: reg
Provision Reference: reg 9 (pt 1/3)
Character Range: 5418–8469

9               Factors that must exist
At least one of the following factors must exist before it can be said that, on the balance of probabilities, immune thrombocytopaenia or death from immune thrombocytopaenia is connected with the circumstances of a person's relevant service:
(1)          having a viral infection from the specified list of viral infections within the six weeks before the clinical onset of immune thrombocytopaenia;
Note: specified list of viral infections is defined in the Schedule 1 - Dictionary.
(2)          having a bacterial or fungal infection from the specified list of bacterial and fungal infections, within the six weeks before the clinical onset of immune thrombocytopaenia;
Note: specified list of bacterial and fungal infections is defined in the Schedule 1 - Dictionary.
(3)          being treated with a drug or a drug from a class of drugs from the specified list of drugs, within the six weeks before the clinical onset of immune thrombocytopaenia;
Note: specified list of drugs is defined in the Schedule 1 - Dictionary.
(4)          receiving a vaccine from the specified list of vaccines within the six weeks before the clinical onset of immune thrombocytopaenia;
Note: specified list of vaccines is defined in the Schedule 1 - Dictionary.
(5)          being treated with a drug or receiving a dose of vaccine which is associated in the individual with the following:
(a)          the development of immune thrombocytopaenia within six weeks of commencing drug therapy or receiving the dose of vaccine; and
(b)          an absence of immune thrombocytopaenia prior to commencing drug therapy or vaccination; and
(c)          sustained recovery from immune thrombocytopaenia on ceasing drug therapy or vaccination; and
(d)          exclusion of other aetiologies for thrombocytopaenia (including other drugs or vaccines);
(6)          being pregnant within the six weeks before the clinical onset of immune thrombocytopaenia;
(7)          having a lymphoproliferative disorder from the specified list of lymphoproliferative disorders, at the time of the clinical onset of immune thrombocytopaenia;
Note: specified list of lymphoproliferative disorders is defined in the Schedule 1 - Dictionary.
(8)          having an autoimmune or inflammatory disorder from the specified list of autoimmune and inflammatory disorders, at the time of the clinical onset of immune thrombocytopaenia;
Note: specified list of autoimmune and inflammatory disorders is defined in the Schedule 1 - Dictionary.
(9)          consuming a food or beverage from the specified list of food and beverages, within the six weeks before the clinical onset of immune thrombocytopaenia;
Note: specified list of food and beverages is defined in the Schedule 1 - Dictionary.
(10)      consuming a food or beverage which is associated in the individual with the following:
(a)          the development of immune thrombocytopaenia within six weeks of consuming the food or beverage; and
(b)          an absence of immune thrombocytopaenia prior